- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04670978
Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer
April 23, 2023 updated by: Beihua Kong, Shandong University
Efficacy and Safety of Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer:A Multi-center, Prospective, One-arm, Phase II Study
The study is a multi-center, prospective, one-arm, phase II clinical trial.
It is tend to examine the safety and efficacy of combining abraxane(albumin-bound paclitaxel) and bevacizumab to treat patients with recurrent, platinum-resistant primary epithelial ovarian cancer, fallopian tube cancer or peritoneal carcinoma.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
96
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Beihua Kong
- Phone Number: 18560081888
- Email: kongbeihua@sdu.edu.cn
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Recruiting
- Qilu Hospital of Shandong University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Recurrent or progressive primary EOC, fallopian tube carcinoma or peritoneal carcinoma (PC) within 6 months of their last previous platinum therapy
- Patients had received at least one prior line of platinum-based chemotherapy
- Patients were required to have one measurable disease for assessment according to RECIST version 1.1 or determined CA125 level according to GCIG
- Eastern Cooperative Oncology Group (ECOG) Performance Status rating of 0-1
- life expectancy ≥3 months
- ≥30 days after surgery, the body has recovered and there is no active infection
- Patients had received at least 1 prior line of platinum-based chemotherapy and were recurrent or progressed within 6 months after the end of the last platinum-based regimen
- Must have adequate hematologic and hepatic function
- Subjects of childbearing age must agree to use effective contraception during the trial period and negative for serum or urine pregnancy test
- Patient provides voluntary written informed consent
Exclusion Criteria:
- Previously received bevacizumab.
- History of other invasive malignancy with the exception of nonmelanoma skin cancer
- Participate in other drug trials
- Blood pressure of >150/100 mmHg on antihypertensive medications
- Previous history of hypertensive crisis or hypertensive encephalopathy
- Diagnosed with unstable angina per NYHA or Grade 2 or greater congestive heart failure
- The history of myocardial infarction within 6 months
- The history of stroke or transient ischemic attack within 6 months of enrollment
- Clinically significant vascular disease (e.g., aortic aneurysm, aortic dissection) or symptomatic peripheral vascular disease
- Bleeding diathesis or coagulopathy
- Presence of central nervous system or brain metastases
- Pre-existing peripheral neuropathy of Grade ≥ 2
- Major surgery was performed within 28 days prior to enrollment
- Partial or complete ileus within 3 months prior to study enrollment
- A biopsy or other minor surgery within 7 days prior to study enrollment
- Positive pregnancy test or is lactating
- Abdominal fistula, gastrointestinal perforation or abscess accumulation in the abdominal cavity within 6 months prior to study enrollment
- Severe, nonhealing wound, ulcer, or bone fracture
- Serious intercurrent medical or psychiatric illness, including serious active infection
- Uncontrolled systemic infections require antiinfective treatment
- Proteinuria at screening as demonstrated by either
- Urine protein:creatinine (UPC) ratio ≥ 1.0 at screening OR
- Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible)
- Known to be allergic, highly sensitive or intolerant to investigational drugs or their excipients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: albumin-bound paclitaxe combined with bevacizumab biosimilar
albumin-bound paclitaxel, 260mg/m2,ivdrip,D1,once every three weeks bevacizumab biosimilar, 10mg/kg,ivdrip,D1, once every three weeks
|
albumin-bound paclitaxe, 260mg/m2, every 3 weeks, 6cycles, bevacizumab biosimilar, 10mg/kg, every 3 weeks, continue until PD or unaccceptable toxicity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
objective response rate
Time Frame: Assessed at the end of 6 cycle(each cycle is 21 days)
|
Radiologic imaging was scheduled to be performed at baseline, after every third treatment cycle, and at the end of treatment or time of progression unless it was done in the previous four weeks.
Response was evaluated using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter of target lesions; objective response rate (ORR) = CR+PR
|
Assessed at the end of 6 cycle(each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6-month progression-free survival rate
Time Frame: assessed up to 6 months
|
the percentage of participants with no progression event at 6 months after starting study treatment
|
assessed up to 6 months
|
progression-free survival
Time Frame: up to 3 years
|
PFS was measured from day 1 of treatment until time of progression (assessed every 12 weeks) or death, whichever came first
|
up to 3 years
|
overall survival
Time Frame: assessed up to 3 years
|
Overall survival is defined as the time from treatment start until death from any cause
|
assessed up to 3 years
|
Disease control rate
Time Frame: Assessed at the end of 6 cycle(each cycle is 21 days)
|
the percentage of complete and partial response as well as stable disease
|
Assessed at the end of 6 cycle(each cycle is 21 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2021
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
December 31, 2024
Study Registration Dates
First Submitted
December 5, 2020
First Submitted That Met QC Criteria
December 11, 2020
First Posted (Actual)
December 17, 2020
Study Record Updates
Last Update Posted (Actual)
April 25, 2023
Last Update Submitted That Met QC Criteria
April 23, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- AB-PRR-EOC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Objective Response Rate
-
Peking Union Medical College HospitalOrigiMedRecruitingQuality of Life | Objective Response Rate | Overall Survival | Progression-free Survival | Disease Control Rate | Duration of Response | Five-year Survival RateChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingObjective Response RateChina
-
Peking University People's HospitalPeking University; Northwestern University; University of ChicagoUnknownHistologic Response (Tumor Necrosis Rate) | Objective Response Rate for Neoadjuvant Chemotherapy, ORR | Progression-free Survival, PFS | Overall Survival, OSChina
-
Leiden University Medical CenterThe Netherlands Cancer Institute; Borstkanker Onderzoek Groep; Comprehensive... and other collaboratorsSuspendedHER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer | Neoadjuvant Chemotherapy | Fasting Mimicking Diet | Pathological Complete Response | Objective Response RateNetherlands
-
Tianjin Medical University Cancer Institute and...Not yet recruitingObjective Response Rate (ORR)
-
University of Southern DenmarkCompleted
-
Shanghai Jiao Tong University School of MedicineCompleted
-
The First Affiliated Hospital with Nanjing Medical...RecruitingAdvanced Breast Cancer | Objective Response Rate | Trastuzumab EmtansineChina
-
Assistance Publique Hopitaux De MarseilleUnknownthe Coagulolytic Balance | the Mortality Rate | the Performance Used to Evaluate the Principal Objective Are Technical Performances, Sensibility and Specificity of the TestsFrance
-
Institut de l'oeil des LaurentidesRecruitingThe Objective of the Study is to Prospectively Compare the Success Rate of ab Externo and Interno ImplantationCanada
Clinical Trials on albumin-bound paclitaxe combined with bevacizumab biosimilar
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7United States, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingPoorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVA Thyroid Gland...United States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedMetastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma AJCC v7United States
-
National Cancer Institute (NCI)Active, not recruitingOvarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditionsUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingChondrosarcoma | Advanced Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous... and other conditionsUnited States
-
Shengjing HospitalRecruiting
-
Peking University Cancer Hospital & InstituteRecruitingGastric AdenocarcinomaChina
-
Guizhou Medical UniversityUnknown
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingOvarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditionsUnited States, Korea, Republic of, Canada